Fallbericht
Remarkable Response to Vismodegib in a Locally Advanced Basal Cell Carcinoma on the Nose
Cutis · 2025
DOI: 10.12788/cutis.1228 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cutis, 2025. Verfasst von Evan Mak und 1 weiteren Autor:innen. Beteiligte Einrichtung: Evan Mak is from the Uniformed Services University of the Health Sciences, Bethesda, Maryland. Dr. Buck is from Landstuhl Regional Medical Center, Ge…. Hauptthemen laut MEDLINE: Anilides, Antineoplastic Agents, Basal Cell Carcinoma, Nose Neoplasms.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
AnilidesAntineoplastic AgentsBasal Cell CarcinomaNose NeoplasmsPyridinesSkin NeoplasmsAgedHumansMohs SurgeryTreatment Outcome
Substanzen
AnilidesAntineoplastic AgentsHhAntag691Pyridines
Autor:innen und Institutionen
- Evan Mak is from the Uniformed Services University of the Health Sciences, Bethesda, Maryland. Dr. Buck is from Landstuhl Regional Medical Center, Germany.
Zitieren
APA
Mak, E., & Buck, S. (2025). Remarkable Response to Vismodegib in a Locally Advanced Basal Cell Carcinoma on the Nose. Cutis. https://doi.org/10.12788/cutis.1228
Vancouver
Mak E, Buck S. Remarkable Response to Vismodegib in a Locally Advanced Basal Cell Carcinoma on the Nose. Cutis. 2025. doi:10.12788/cutis.1228
BibTeX
@article{Mak2025,
author = {Mak, Evan and Buck, Shannon},
title = {Remarkable Response to Vismodegib in a Locally Advanced Basal Cell Carcinoma on the Nose},
journal = {Cutis},
year = {2025},
doi = {10.12788/cutis.1228}
}
EUVIMED